ArticleBiomaterials2013
Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 354 citations in OpenAlex.
- Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy.Bioactive materials · 2027Article
- Research advances on tumor-associated macrophages in pancreatic cancer.Biochemistry and biophysics reports · 2026Review
- High-Throughput Generation of Tumor Spheroids via Droplet Microfluidics for siRNA-Loaded Nanomedicine Assessment.Advanced healthcare materials · 2026Article
- Advances in hyaluronic acid-based biomaterials: applications in cancer therapy, wound healing, and disease management.Journal of materials science. Materials in medicine · 2025Review
- Drug-loaded nanoparticles induce immunogenic cell death and efficiently target cells from glioblastoma patients.Nanomedicine (London, England) · 2025Article
- Revolutionizing mRNA Vaccines Through Innovative Formulation and Delivery Strategies.Biomolecules · 2025Review
- Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes.Nanomedicine (London, England) · 2025Article
- Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.Cancer cell international · 2024Review
- Bimetallic peroxide nanoparticles induce PANoptosis by disrupting ion homeostasis for enhanced immunotherapy.Science advances · 2024Article
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.Medical oncology (Northwood, London, England) · 2024Review
- Potentiating Gilteritinib Efficacy Using Nanocomplexation with a Hyaluronic Acid-Epigallocatechin Gallate Conjugate.Polymers · 2024Article
- Targeted Delivery of Geraniol via Hyaluronic Acid-Conjugation Enhances Its Anti-Tumor Activity Against Prostate Cancer.International journal of nanomedicine · 2024Article
- Hyaluronic Acid Nanogels: A Promising Platform for Therapeutic and Theranostic Applications.Pharmaceutics · 2023Review
- Review
- Cluster of Differentiation 44 Expression in Gastrointestinal Malignancies: A Study from South India.Journal of laboratory physicians · 2023Article
- Review
- Advances in transdermal siRNAs delivery: A review of current research progress.Non-coding RNA research · 2023Review
- Polymeric-Micelle-Based Delivery Systems for Nucleic Acids.Pharmaceutics · 2023Review
- Review
- LXR inhibitor SR9243-loaded immunoliposomes modulate lipid metabolism and stemness in colorectal cancer cells.Medical oncology (Northwood, London, England) · 2023Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Anticancer therapeutics employing RNA interference mechanism holds promising potentials for sequence-specific silencing of target genes. However targeted delivery of siRNAs to tumor tissues and cells and more importantly, their intracellular release at sites of interest still remains a major challenge that needs to be addressed before this technique could become a clinically viable option. In the current study, we have engineered and screened a series of CD44 targeting hyaluronic acid (HA) based self-assembling nanosystems for targeted siRNA delivery. The HA polymer was functionalized with lipids of varying carbon chain lengths/nitrogen content, as well as polyamines for assessing siRNA encapsulation. From the screens, several HA-derivatives were identified that could stably encapsulate/complex siRNAs and form self-assembled nanosystems, as determined by gel retardation assays and dynamic light scattering. Many HA derivatives could transfect siRNAs into cancer cells overexpressing CD44 receptors. Interestingly, blocking the CD44 receptors on the cells using free excess soluble HA prior to incubation of cy3-labeled-siRNA loaded HA nano-assemblies resulted in >90% inhibition of the receptor mediated uptake, confirming target specificity. In addition, SSB/PLK1 siRNA encapsulated in HA-PEI/PEG nanosystems demonstrated dose dependent and target specific gene knockdown in both sensitive and resistant A549 lung cancer cells overexpressing CD44 receptors. More importantly, these siRNA encapsulated nanosystems demonstrated tumor selective uptake and target specific gene knock down in vivo in solid tumors as well as in metastatic tumors. The HA based nanosystems thus portend to be promising siRNA delivery vectors for systemic targeting of CD44 overexpressing cancers including tumor initiating (stem-) cells and metastatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.